The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Changing front-line therapy in MDS and AML
In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, highlights the current and future of frontline therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Dr Sallman first mentions the results from the PANTHER trial (NCT03268954), which investigated the use of pevonedistat plus azacitidine versus azacitidine monotherapy as first-line treatment for patients with MDS and AML. Following this, Dr Sallman mentions some novel options being explored for frontline therapy, drawing focus on targeted inhibitors and intensive chemotherapy, and the hope that novel cellular therapies will be made more available to patients with MDS. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
